The patented technology comprises a lipid-based matrix and a non-biodegradable polymer, in which one or more active pharmaceutical ingredients (API) can be held, can be formulated to release them at a pre-programmed rate for up to several months.
The first PolyPid-based solution is BonyPid, the Israeli firm’s own biodegradable bone void filler; however, the technology is suitable for a wide range of pharmaceutical controlled release delivery applications according to CTO Noam Emanuel.
"Due to its flexibility, the PolyPid platform can be utilized to address numerous medical indications in various fields, such as orthopaedics, urology, periodontal, anti-cancer/anti-fungal treatments and surgical accessories."